Pangea Bio
PrivateLast Round
Grant
Oct 20, 2025
Total Funding Raised
$16.6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Pangea Bio operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Grant round in October 2025.
Pangea Bio is a biotechnology company developing transformative medicines to treat neurological and neuropsychiatric conditions by using AI to unlock nature's neuroactive chemistry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pangea Bio Comparables
Compare Pangea Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sensorium Therapeutics | 88% | |
| MThera Pharma | 81% | |
| Forecast Bio, Inc. | 79% |
For institutional investors. Book with your work email.
Pangea Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 20, 2025 | ||||
| Grant | Aug 22, 2024 | ||||
| Accelerator | Mar 5, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pangea Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Playfair Capital | Series A |
| F4 Fund | Series A |
| Metaplanet Holdings | Series A |
| One Mind | Series A, Accelerator |
| Innovate UK | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant, Series A |
| No Label Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased from 0 to 23, representing 88% of headcount.
- Jan 7, 2026
Monthly visitors increased 59% MoM, reaching 2.4K.
For institutional investors. Book with your work email.
Pangea Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pangea Bio's valuation, stock price, and market status.
Is Pangea Bio a public or private company?
Pangea Bio is a private company.
What is the current stock price of Pangea Bio?
Pangea Bio is a private company, so its shares have no public market price. Caplight tracks Pangea Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pangea Bio worth (valuation)?
Valuation information for Pangea Bio is not publicly available.
Can I buy Pangea Bio stock?
Pangea Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pangea Bio's last funding round?
Pangea Bio's most recent funding round was Grant on October 20, 2025.
Who are the main investors in Pangea Bio?
Key investors in Pangea Bio include Playfair Capital, F4 Fund, Metaplanet Holdings, One Mind, Innovate UK.
Will Pangea Bio IPO soon?
No public IPO plans have been announced for Pangea Bio.
How can I track Pangea Bio secondary market activity?
Caplight tracks bids, offers, and trades in Pangea Bio's shares on secondary markets.